• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients.

作者信息

Eljaaly Khalid, Al-Tawfiq Jaffar A

机构信息

Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; Pharmacy Practice and Science Department, College of Pharmacy, University of Arizona, Tucson, AZ, USA.

Infectious Disease Unit, Specialty Internal Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia; Department of Medicine, Indiana University, School of Medicine, Indianapolis, IN, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

出版信息

Travel Med Infect Dis. 2020 Nov-Dec;38:101749. doi: 10.1016/j.tmaid.2020.101749. Epub 2020 May 28.

DOI:10.1016/j.tmaid.2020.101749
PMID:32473994
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7263273/
Abstract
摘要

相似文献

1
Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients.碾碎洛匹那韦-利托那韦片可能会降低其对新冠病毒肺炎患者的治疗效果。
Travel Med Infect Dis. 2020 Nov-Dec;38:101749. doi: 10.1016/j.tmaid.2020.101749. Epub 2020 May 28.
2
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.洛匹那韦/利托那韦未能缩短台湾轻症肺炎患者 SARS-CoV-2 脱落持续时间。
J Microbiol Immunol Infect. 2020 Jun;53(3):488-492. doi: 10.1016/j.jmii.2020.03.032. Epub 2020 Apr 3.
3
Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.洛匹那韦/利托那韦治疗严重急性呼吸综合征、中东呼吸综合征和 COVID-19：系统评价。
Eur Rev Med Pharmacol Sci. 2020 Aug;24(16):8592-8605. doi: 10.26355/eurrev_202008_22659.
4
Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.早期给予利托那韦增强型洛匹那韦可预防重症新型冠状病毒肺炎。
J Infect. 2021 Jan;82(1):159-198. doi: 10.1016/j.jinf.2020.05.039. Epub 2020 May 27.
5
Predictive association of C3435T genetic polymorphism with the efficacy or safety of lopinavir and ritonavir in COVID-19 patients.C3435T 基因多态性与洛匹那韦和利托那韦治疗 COVID-19 患者的疗效或安全性的预测关联。
Pharmacogenomics. 2021 Apr;22(6):375-381. doi: 10.2217/pgs-2020-0096. Epub 2021 Mar 24.
6
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.抗 SARS-CoV-2 再利用抗病毒药物的临床试验。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01101-20.
7
Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.洛匹那韦/利托那韦联合治疗非重症 COVID-19 患者中病毒动力学及快速病毒清除相关因素。
Eur Rev Med Pharmacol Sci. 2020 May;24(10):5788-5796. doi: 10.26355/eurrev_202005_21373.
8
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.新加坡 2019 年新型冠状病毒肺炎患者的流行病学特征和临床病程
JAMA. 2020 Apr 21;323(15):1488-1494. doi: 10.1001/jama.2020.3204.
9
Treating COVID-19 with Chloroquine.用氯喹治疗新型冠状病毒肺炎。
J Mol Cell Biol. 2020 May 18;12(4):322-325. doi: 10.1093/jmcb/mjaa014.
10
Combating COVID-19 with Chloroquine.用氯喹抗击新冠病毒。
J Mol Cell Biol. 2020 May 18;12(4):249-250. doi: 10.1093/jmcb/mjaa015.

引用本文的文献

1
A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections.一项随机、双盲、多中心临床研究，比较洛匹那韦/利托那韦-阿奇霉素、洛匹那韦/利托那韦-多西环素以及阿奇霉素-羟氯喹联合用药对诊断为轻至中度新型冠状病毒肺炎感染患者的疗效和安全性。
Biochem Res Int. 2021 Feb 9;2021:6685921. doi: 10.1155/2021/6685921. eCollection 2021.
2
Global contributions of pharmacists during the COVID-19 pandemic.药剂师在新冠疫情期间的全球贡献。
J Am Coll Clin Pharm. 2020 Dec;3(8):1480-1492. doi: 10.1002/jac5.1329. Epub 2020 Oct 2.
3
Hydroxychloroquine safety: A meta-analysis of randomized controlled trials.羟氯喹安全性：一项随机对照试验的荟萃分析。
Travel Med Infect Dis. 2020 Jul-Aug;36:101812. doi: 10.1016/j.tmaid.2020.101812. Epub 2020 Jul 6.

本文引用的文献

1
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
2
Remdesivir as a possible therapeutic option for the COVID-19.瑞德西韦作为治疗新冠肺炎的一种可能选择。
Travel Med Infect Dis. 2020 Mar-Apr;34:101615. doi: 10.1016/j.tmaid.2020.101615. Epub 2020 Mar 5.
3
Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.洛匹那韦利托那韦的药代动力学：粉碎与整片制剂在儿童中的比较。
J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):385-91. doi: 10.1097/QAI.0b013e318232b057.